IJGII Inernational Journal of Gastrointestinal Intervention

pISSN 2636-0004 eISSN 2636-0012
ESCI

Article

home All Articles View

Review Article

Gastrointestinal Intervention 2017; 6(1): 70-77

Published online March 31, 2017 https://doi.org/10.18528/gii160034

Copyright © International Journal of Gastrointestinal Intervention.

Percutaneous intervention for bilioenteric anastomotic strictures: Current strategies and future directions

Rayhan Hai, and Joshua Kuban*

Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Correspondence to:Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1471, Houston, TX 77030, USA. E-mail address:JDKuban@mdanderson.org (J. Kuban).

Received: December 6, 2016; Revised: March 2, 2017; Accepted: March 2, 2017

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Postoperative bilioenteric anastomotic strictures are encountered in a significant number of patients after primary biliary repair, hepatopancreaticobiliary tumor resection, and liver transplantation. Due to difficulties with repeat surgery and endoscopic access, percutaneous dilation has become the accepted treatment in these cases. While the overall paradigm of percutaneous access, balloon dilation, and catheter stenting remains consistent, institutional protocols differ in several technical variables including balloon sizes, inflation techniques, catheter sizing, and overall time course of treatment, amongst others. The current review aims to discuss various treatment protocols and their relative efficacy, as well as touch on emerging techniques.

Keywords: Biliary tract, Constriction, pathologic, Radiology, interventional, Stents

Surgeries involving the creation of bilioenteric anastomoses are performed in patients for a variety of reasons including primary repair of benign biliary strictures, tumor resection, and liver transplantation. Anastomotic strictures are generally thought to form due to fibrosis with resultant retraction, as opposed to non-anastomotic benign biliary strictures which often occur due to iatrogenic causes (most commonly during cholecystectomy), chronic biliary inflammation, or ischemia during hepatic transplant.1

Benign stricturing of the bilioenteric anastomosis is significant problem, occurring in 8%–40% of cases of primary biliary repair, with biliary complications occurring in 11.5%–34% of liver transplants.2,3 Postoperative strictures at the hepaticojejunostomy develop in 2.6% of patients who undergo pancreaticoduodenectomy at a high volume center.4 Repeat surgical interventions often result in poorer outcomes, with greater rates of morbidity and mortality correlating with the number of previous repairs.5 Endoscopic treatment of benign bilioenteric anastomotic strictures (BAS) is difficult in altered surgical enteric anatomy and these patients are often referred for percutaneous treatment.6 Unlike treatment of malignant strictures, these patients may have extended survival and are not good candidates for traditional self-expandable metallic stents7,8 or prolonged percutaneous transhepatic drain placement.

Definitive percutaneous treatment of benign biliary strictures was first described by Molnar and Stockum9 in 1978, and again in a larger series by Mueller et al10 in 1986. Since this time there has been evolution of tools and technique. Current protocols for percutaneous treatment of BAS are varied in their technique and success rates. We aim to review some of the current techniques used for percutaneous treatment of bilioenteric strictures, examine short and long-term outcomes of the more common protocols, and comment on future directions of the procedure (Table 1).

The classic symptoms of cholestasis including jaundice and pruritus are generally the first evidence of the occurrence of a biliary stricture, anastomotic or otherwise. These symptoms often occur with the expected laboratory abnormalities including a rising bilirubin, alkaline phosphatase, and γ-glutamyltransferase (the cholestatic pattern), as well as mild increases in the transaminases.11 In many cases the first sign of a biliary stricture is frank cholangitis, with presenting symptoms of fever, abdominal pain, jaundice, and rigors. Generally some form of medical imaging is then performed demonstrating intrahepatic biliary dilation with identification of a biliary stricture (Fig. 1).

Terminology can vary, though for the purposes of this review, each case in which balloon dilation is performed is referred to as a dilation procedure, of which several may occur in a single dilation session. Dilation sessions are concluded once the desired stricture diameter is attained. A single treatment consists of one or multiple dilation sessions separated by intervals of catheter stenting. The treatment is concluded once all catheters are removed from the patient. Should a stricture recur after conclusion of a treatment, it is considered a treatment failure.

Catheter-based upsizing

Percutaneous biliary interventions are among the most painful minimally invasive procedures that are routinely performed, necessitating expert sedation to maintain patient comfort. Most of the recent series conducting balloon dilations are able to effectively treat patients using moderate sedation with intravenous midazolam and fentanyl as for most interventional procedures. However, some interventionalists promote the use of general anesthesia for these procedures, citing not only the improved pain relief for the patient, but the ability to more aggressively dilate during the procedure.12 Trambert et al13 suggest the use of 1% Li-docaine administered directly into the biliary tree before dilation as a useful adjunct to opiate analgesia. At our institution, general anesthesia is routinely used for biliary dilation and stenting procedures.

Access and staging

The first report by Molnar and Stockum9 described a three phase approach to percutaneous dilation of choledochoenterostomy strictures. Phase I involved percutaneous access and placement of an external drain, phase II involved placement of an internal/external drain, and phase III involved balloon dilation of the stricture (Fig. 2). The period of time between initial biliary drainage and the first dilation allows for an opportunity for the patient’s symptoms and lab values to normalize. This is especially important if the patient is actively cholangitic, as manipulation of a fresh intraparenchymal tract increases the exposure of hepatic venous blood to bile, with resultant increased risk of sepsis. Staging the procedure allows maturation of the percutaneous transhepatic tract. Most protocols for biliary dilation follow the general staged protocol initially described by Molnar and Stockum.9 The period of time between initial biliary drainage and balloon dilation varies, with some waiting a period of 1–4 days,2,14 and others advocating a period of weeks.2,14,15 Several of the large series evaluating percutaneous dilation over the last decade however routinely conduct their first balloon dilations on the initial day of access.1619 The study by Choo et al15 used the longest delay of 4–6 weeks between access and initial dilation, though did not have a significantly lower complication rate. However, treatment subjects in that study were exclusively post-transplant, confounding a direct comparison. Factors such as patient acuity, ease of percutaneous access, level of pre-stenotic biliary dilation, severity of stricture, ease of crossing the stricture with a guide wire, and various logistical and economic factors all play a role.

Balloon diameter

Due to the considerable fibrosis associated with anastomotic strictures, initial dilation is often difficult.10 Definitive treatment balloon diameter is determined based on the estimated normal duct diameter, persistence of the stricture, and concern for rupture. Because of stricture elasticity, some operators advocate for use of balloon diameters 25%–30% larger than the normal duct.1,15 Most commonly 8–10 mm20 are used, though balloon sizes up to 15 mm have been reported without an associated increase in complictions.1 Short term recurrence of the stricture suggests that the balloon diameter used was too small or the balloon pressure was not great enough to fracture the scar.21 Of note, some interventionalists have opted to avoid balloon dilation altogether, instead utilizing sequential bougie dilation with good result.14

Balloon inflation pressure

As with dilation procedures elsewhere in the body, high-pressure low-compliance balloons are typically used for biliary stricture dilation. Most protocols do not specify a particular pressure for inflation. At our institution the balloon is expanded to its rated pressure in a gradual fashion, with use of a larger diameter balloon or possibly cutting balloon should the current balloon prove insufficient to dilate the stricture.

Balloon inflation duration

There is wide variation in the duration of balloon inflation during a given dilation procedure, ranging from 10 seconds to 12 hours.15,2123 In his initial description, Molnar and Stockum9 inflated their balloons for approximately 1–3 minutes, which remains the most commonly used inflation time today.9,12,16,19,20 There has been no documented difference in outcome between short and long dilation times, and several institutions do not specify a specific time on their protocols. Of the largest studies in the past decade, the shortest inflation time of 10–30 seconds was associated with a treatment failure rate of 17%,15 while the longest inflation time of 3 minutes was associated with a treatment failure rate of 23%.16 Overnight inflation for 8–12 hours with alternating 1 hour inflation and deflation periods has been described23 but is cumbersome, costly, and is not widely used.

Stent catheter placement

Once the stenosis has been balloon dilated to an appropriate size, the tract is generally stented with an internal/external biliary catheter to allow healing of the fractured stricture while maintaining patency of the anastomosis and access to the biliary tree. Catheter sizes range from 8.5 F to 18 F (Fig. 3). Proponents of stenting with large caliber (16–18 F) catheters argue that the insertion of the large caliber catheter is more important to treatment than balloon dilation.21 This strategy is supported by the efficacy of endoscopic placement of multiple endoprostheses to dilate the stricture.24 Detractors of this strategy have pointed out that dilating the entire biliary tract can cause undue morbidity and are not as well tolerated by patients.10 No direct comparison of catheter size on long-term treatment outcome has been performed. Of the most recent larger trials, Vos et al20 used the smallest catheters (8.4 F) in their protocol, with a treatment failure rate of 27%. Choo et al15 used among the largest catheters (14–18 F) in their protocol, with a treatment failure rate of 17%15 suggesting that larger bore catheters may be superior.

Stent duration and repeat dilation

Once the stent catheter has been placed, it has to be maintained long enough that the ballooned stricture has time to heal around it. This is supported by the finding that anastomotic patency is better when surgically-placed stents are in place for longer than 1 year.5 Most of the major series over the past decade have used treatment durations of close to 1 year, with a few opting for slightly shorter stenting times of 3–6 months.2,14,1618,25 Weber et al14 employed the longest treatment duration (mean, 19.9 months) with a treatment failure rate of 39%. Proponents of short-term stenting (up to one month) argue equivalent efficacy with less inconvenience to the patient.10,19 The trial conducted by Cantwell et al19 used the shortest treatment duration (mean, 1.1 months), and observed the largest treatment failure rate of 44%. Some maintain the stenting catheter only between balloon dilation procedures, removing it as soon as maximal balloon dilation is achieved. Lee et al12 used this approach (mean stenting duration of 10 days), with a treatment failure rate of only 7%; however, this was only in a small group of patients. Saad and colleagues26,27 described a treatment protocol whereby if the stenosis has not been adequately treated after three dilation sessions (maximum stenting duration of 6 weeks), it is considered a treatment failure; this protocol saw a treatment failure rate of 64%.

Long term maintenance of an indwelling biliary stent catheter requires routine exchanges to ensure continued patency of the catheter, evaluate the stricture and perform repeat dilation when necessary. The most common interval for exchange and repeat cholangiography is 3 months, used in the majority of the most recent series. However some operators advocate more frequent exchanges, with some intervals on the order of a few days.19 Bonnel and Fingerhut2 speculate that the greater success rate observed in their study (treatment failure rate of 15%) compared to other recent series may be due to their choice of a relatively shorter interval between exchanges/dilations of 1.5 months. It has also been speculated that longer time intervals between balloon dilations may result in more focal fibrosis at the stricture site due to interval healing.1 At our institution, an exchange frequency of every 3 months is most commonly used.

Catheter-based upsizing

Some protocols use sequential stricture dilation with catheters, rather than balloon inflation, as the main mechanism of treatment. It is hypothesized that the longer-term catheter dilation allows healing of the stricture around the catheter, determining the overall end result.21 DePietro et al25 conducted a recent trial using catheter upsizing every two weeks until an optimal size was reached (generally 16–18 F), at which point the catheter was maintained for 6–12 months. Balloon dilation was performed when an optimal size catheter could not be placed. They demonstrated a treatment failure rate of 33%. This protocol is similar to that used by Schumacher et al28 and Weber et al,14 with treatment failure rates of 25.8% and 39%, respectively.

Minor complications related to percutaneous biliary interventions commonly include post-dilation fever and chills, tube displacement, pericatheter leakage, and gallstones.25 Major complications include cholangitis/sepsis, bile leak, and hemorrhagic complications including pseudoaneurysm and hemobilia, some requiring catheter embolization. In the most recent series, rates of bile leak/biloma formation range from 0%–6.3%, while rates of hemorrhagic complications range from 0%–5% (with the exception of Choo et al15 which demonstrated a hemorrhagic complication rate of 16.6%). Direct comparison of complication rates is difficult as reporting and classification of complications is quite variable. To date, no specific procedural factor has been associated with a significant increase or decrease in complication rate.

Balloon dilation is usually performed until abolition of the waist is observed. How aggressively to upsize balloons is best judged on a case-by-case basis, but most agree that once the balloon waist has decreased to less than 20% of its initial size, dilation has been sufficient.15 The ease of passage of contrast is a useful adjunct in determining stricture patency and incomplete drainage after 5 minutes is an indication for continued dilation.28 In the case of multiple dilation procedures in a single session, a dilated stricture may not show improvement on the immediate post-procedure cholangiogram due to edema within the duct immediately post-dilation.13 Significant improvement may not be seen until the pre-dilation cholangiogram during the subsequent procedure.

Determination of success of dilation treatment is often accompanied by a clinical ‘clamping’ trial. This consists of removal of catheter access across the stricture placement of a small caliber external biliary drain. This catheter is then capped and the patient monitored over a time course of a few weeks to a few months.17,21 Signs of stricture recurrence including jaundice, abdominal pain, cholangitis, or laboratory abnormalities would be an indication for repeat cholangiogram through the maintained access. Should the patient remain asymptomatic for the treatment period, the catheter can be removed, either in clinic or after a final follow-up cholangiogram.

Once stenting has been maintained for longer than 1 year without desired clinical result, treatment is unlikely to be successful.28 At this point, the patient is best either referred to surgery for attempt at repair, or maintained with permanent internal/external drainage. Endoscopic literature agrees that there is no benefit from stenting beyond 1 year.6 Some interventionalists are more persistent, suggesting that surgical intervention be pursued after drainage is attempted for 24 months.14 The protocol put forth by Saad27 targets a < 30% residual stenosis to define success; if there is no improvement in any single dilation session or if < 30% residual stenosis cannot be achieved after an arbitrary maximum of three dilation sessions, the treatment is considered a failure. At our institution, we have found success with balloon dilation and catheter upsizing every 1–2 months, with no response after 4–5 dilations or 1 year considered a failure.

Before performing percutaneous balloon dilation, a full biochemical laboratory analysis including complete blood count, comprehensive metabolic profile including a liver panel, and a coagulation profile should be obtained. In accordance with the Society of Interventional Radiology guidelines, platelets should be maintained above 50,000 and the international normalized ratio below 1.5 if a new biliary tract is being created. Aspirin should be held for 5 days if a new biliary tract is being created; Clopidigrel should be held for 5 days regardless.29 Biliary procedures are considered clean-contaminated, and as such antibiotic prophylaxis against predominantly gram negative organisms should be used. Common antibiotic choices include intravenous ceftriaxone, ampicilin/sulbactam, and clindamycin with an aminoglycoside.30 Significant ascites should be drained prior to the procedure. Contraindications to balloon dilation include massive ascites, a shrunken cirrhotic liver which cannot be accessed safely (i.e., no available approach without traversing pleura or bowel), and uncorrectable coagulopathy.22

Overnight observation is suggested when a new percutaneous access is being placed. Subsequent dilations and catheter exchanges can usually be performed on an outpatient basis. However, operators should remain vigilant for signs of sepsis or other complications which would necessitate a hospital admission.

There is no formal protocol for maintenance of the stenting catheter by the patient between dilation sessions. At our institution, daily flushing of the catheter with 10 mL of normal saline is used to ensure continued catheter patency. This requires adequate patient education and motivation. We also routinely prescribe prophylactic ursodiol to help solubilize cholesterol and lower the incidence of stone formation. The medication is prescribed at 300 mg by mouth twice daily, indefinitely.

BAS can develop several years after the creation of the anastomosis, with only 36% of recurrences developing during the first postoperative year.31,32 Similarly, strictures can recur years after percutaneous treatment, making long-term patient follow up a priority. Recent studies by DePietro et al25 and Janssen et al18 demonstrate the longest follow-up period, with recurrence rates rising from 5%–16% at 1 year to 28%–33% at 10 years.

Cutting balloons

Cutting balloons have become increasingly used in the context of benign biliary strictures, especially when strictures prove refractory to dilation with conventional angioplasty balloons. The embedded blades create small controlled incisions which score the stricture, allowing for a more effective subsequent dilation by the balloon via crack propagation. Case reports by Kakani et al33 and Sheridan and Maclennan34 have shown successful treatment using cutting balloons without the need for catheter stenting, and have shown continued patency for 10 months and 3 years respectively. Indeed, cutting balloons are often used at our own institution with good result (Fig. 4). A small series of 11 patients conducted by Atar et al35 showed the utility of cutting balloon dilation followed by conventional balloon dilation in biliary and ureteral strictures, with technical success achieved in 82% without evidence of ductal rupture. They too did not employ long-term catheter stenting. Saad et al36 conducted a trial involving 22 patients using a protocol featuring multiple sessions of cutting balloon dilation followed by conventional balloon dilation, separated by short-term small caliber catheter stenting. They demonstrated a technical success rate of 93% with this protocol, without evidence of biliary rupture. Minor hemobilia was encountered in 10%. This risk can be minimized by ensuring the diameter of the cutting balloon does not exceed the estimated normal diameter of the duct, reserving over-dilation for the conventional balloon.

Certain technical aspects must also be mentioned when using cutting balloons. First, because of the embedded blades, caution must be taken by the operator when handling the balloon catheter outside of the patient. Second, a slow inflation is recommended so as not to induce undue trauma to the duct. Third, a slow deflation is also recommended to allow for retraction of the blades into their grooves. Should the blades remain exposed as the catheter is retracted, severe complications may occur. Lastly, withdrawing the cutting balloon catheter through the sheath can result in splaying of the tip of the sheath. Thus when the sheath is eventually removed, careful inspection should be undertaken to ensure no fragments of the sheath are inadvertently left in the patient.27,36

Self-expanding bare metal stents

Placement of bare metallic stents have little role in benign biliary strictures and are reserved for patients with < 2 year life expectancy or those expected to receive transplant relatively soon.7,8

Covered self-expanding metal stents

Fully covered self-expanding metallic stents have been increasingly used to substitute for the placement of an internal/ external biliary catheter for anastomotic stenting after balloon dilation (Fig. 5). These stents allow for effective dilation of the anastomotic stricture without the issues brought about by large caliber internal/external catheters, including the necessity of dilating the entire tract and patient discomfort. The stent covering limits potential mucosal ingrowth and hyperplasia, factors which lead to occlusion and difficult retrieval in uncovered metallic stents.37,38 These stents, however, do require retrieval via endoscopy, which as stated before is extremely technically challenging when having to navigate the altered post-surgical anatomy. We have found success at our institution using a rendezvous procedure for retrieval, where percutaneous access is maintained with a small caliber 8 F external biliary drain after initial stent placement. After 6 months of stenting, repeat cholangiogram and stent retrieval can be performed. Through the percutaneous access, a guidewire is advanced through the stent into the bowel where it is then grasped by the endoscope. The guidewire is subsequently retracted, pulling the endoscope into the biliary tract where the stent can then be retrieved (Fig. 6). In situations when this approach is unusable, techniques for percutaneous stent retrieval also exist.39,40 While a dwell time of 6 months is used at our institution, no optimal dwell time has yet been established. Potential complications of retrievable stents include migration, side branch occlusion, and stent degradation with subsequent difficulty of removal.40,41 Of note, the WallFlex covered stent is not yet approved in the United States for endoscopic retrieval.

Dissolvable stents

Dissolvable stents made from polydioxanone (Fig. 7) are becoming increasingly mentioned in the literature as an effective tool, allowing for long-term dilation without the need for removal.42 Hydrolytic degradation of the stent begins after approximately 4 weeks and results in complete absorption within 6 months. Case reports by Petrtýl et al42 and Jones et al43 describe continued patency at 10-month and 2-year follow-up, respectively. The trial conducted by Mauri et al44 demonstrated continued patency at a median follow up time of 16.5 months with complete dissolution of all implanted stents by 6 months. Biliary obstruction due to fragmentation of the stent is a potential complication resulting in transient cholangitis, though is likely less pronounced in the context of a bilioenteric anastomotic stricture.40

Drug eluting stents

The benefits of paclitaxel-coated stents are well established in treating vascular stenosis.45 Animal studies examining the use of paclitaxel-coated dissolvable stents in the context of BAS have demonstrated decreased granulation tissue, inhibited myofibroblast activity, and reduction in extracellular matrix over-deposition compared to controls, without significant difference in liver function.46 Human trials have only been conducted in the context of malignant biliary strictures, demonstrating no significant difference in patency rates compared to non-drug eluting covered stents, though with a trend toward improved patency and survival for the drug eluting stents.47 Additional work with other drugs and drug combinations including various antibiotics and chemotherapy agents is ongoing.48

Percutaneous dilation remains a safe and effective approach to benign biliary strictures, especially in post-surgical strictures at the bilioenteric anastomosis. While numerous variations in procedural technique exist, the basic paradigm of percutaneous access followed by balloon dilation and catheter stenting is followed at most institutions. Differences in protocol are largely anecdotal, with no current evidence-based research demonstrating the superiority of any particular technique. However the use of large bore stent catheters have shown better success overall than small bore catheters. Further studies directly comparing different protocols will need to be carried out to determine which are most efficacious. However, multiple emerging techniques including the use of cutting balloons, retrievable stents, biodegradable stents, and drug-eluting stents have shown early promise, and should become valuable additions to the percutaneous dilation toolbox.

Fig. 1. Coronal magnetic resonance cholangiopancreatography (MRCP)-echoplanar fast spin echo sequence showing focal filling defect at the hepaticojejunostomy in a 77-year-old female with jaundice 3 months after robotic pancreaticoduodenectomy.
Fig. 2. Illustration of three phase balloon dilation technique originally described by Molnar and Stockum (Radiology. 1978;129:59–64) with permission. (a) The catheter is in position for external drainage; (b) it is introduced across the stricture to provide internal drainage; (c) the balloon catheter, positioned in the poststenotic area, is set for dilatation. Rt, right; Lt, left.
Fig. 3. A 12 F internal/external biliary drain (arrow) (Cook Medical, Bloomington, IN, USA). An 18 F silicone biliary catheter with 6.3 F Van-Andel dilation catheter used as an internal stiffener (arrowhead) (Bentec Medical, Woodland, CA, USA; Cook Medical).
Fig. 4. Flextome Cutting Balloon Dilatation Device (Boston Scientific, Natick, MA, USA).
Fig. 5. WallFlex Biliary Fully Covered Stent (Boston Scientific, Natick, MA, USA).
Fig. 6. (A) Cholangiogram demonstrates a biliary stricture at the hepaticojejunostomy recalcitrant to balloon dilation. (B) A fully covered Viabil stent (Gore, Flagstaff, AZ, USA; arrow) has been placed across the stricture with resultant antegrade flow of contrast. (C) A percutaneous wire has been advanced into the afferent jejunal limb and grasped by the endoscope. The wire is used to pull the endoscope into position to retrieve the stent. (D) Completion cholangiogram showing resolution of the stricture post stent removal. The catheter was subsequently removed.
Fig. 7. SX-ELLA Esophageal Degradable Stent (Ella-CS, Trebes, Czech Republic).

Published Case Series of Percutaneous Biliary Stricture Dilation

Vos20Schumacher28Saad26Choo15Köcher16Glas17Cantwell19Weber14Bonnel2Janssen18DePietro25
Year20002001200520062007200820082009201220142015
No. of patients15343812203963441109871
Time between initial percutaneous access and balloon dilation (day)0N/ANot mentioned28–42000–433074
Caliber of balloon (mm) or Bougie (F)6–10N/A6–146–1210–127–1410–12Bougie 16 F104–103–14
Balloon inflation time3 minNot mentioned1–5 min10–30 sec3 minNot mentioned1–3 minN/ANot mentionedNot mentionedNot mentioned
Balloon inflation pressure960 kPaNot mentioned> 12–15 atm6–8 atmUp to 10 atmNot mentionedNot mentionedN/ANot mentionedNot mentionedNot mentioned
Time interval between dilations (mo)Not mentioned30.25–0.32330.07–0.531.50.750.5
Caliber of stenting catheter (F)8.416–188–1214–18141510–1216148.5–128–24
Criterion for definitive catheter removalDirect cholangiographyDirect cholangiographyDirect cholangiography/clamp ing trialDirect cholangiographyDirect cholangiography/clamping trialDirect cholangiographyDirect cholangiographyDirect cholangiographyDirect cholangiographyDirect cholangiography/clamping trialDirect cholangiography/clamping trial
Immediate success (%)9391.2859295971001009998.587
Dilation sessions (n)4 (median)Not mentioned1.2 (mean)2 (mean)Not mentioned3 (mean)2 (mean)7.8 (mean)5 (mean)1.4 (mean)2 (mean)
Duration of stenting (mo)Not mentioned7 (mean)1.5 (maximum)5 (mean)10.3 (mean)11.5 (mean)1.1 (mean)19.9 (mean)8.5 (mean)3.3 (median)6.3 (mean)
Hemorrhagic complication (%)6.75.88216.6052.34.53.60.70
Bile leak/bilomas (%)002002.52.306.300
Morbidity (%)6.723.5433.31051.2Not mentioned11.4108.283 (1% major)
Mortality (%)00000000000
F/U duration (mo)30 (mean)24 (mean)1219 (mean)62 (mean)27.7 (median)96 (mean)53.7 (mean)59 (median)35 (median)56.4 (mean)
Treatment failure* (%)2726641723304439153833

N/A, not applicable; F/U, follow-up.

*Recurrence of obstruction symptoms or visualized stricture.

  1. Zajko, AB, Sheng, R, Zetti, GM, Madariaga, JR, and Bron, KM (1995). Transhepatic balloon dilation of biliary strictures in liver transplant patients: a 10-year experience. J Vasc Interv Radiol. 6, 79-83.
    Pubmed CrossRef
  2. Bonnel, DH, and Fingerhut, AL (2012). Percutaneous transhepatic balloon dilatation of benign bilioenteric strictures: long-term results in 110 patients. Am J Surg. 203, 675-83.
    Pubmed CrossRef
  3. Schwartz, DA, Petersen, BT, Poterucha, JJ, and Gostout, CJ (2000). Endoscopic therapy of anastomotic bile duct strictures occurring after liver transplantation. Gastrointest Endosc. 51, 169-74.
    Pubmed CrossRef
  4. House, MG, Cameron, JL, Schulick, RD, Campbell, KA, Sauter, PK, and Coleman, J (2006). Incidence and outcome of biliary strictures after pancreaticoduodenectomy. Ann Surg. 243, 571-6.
    Pubmed KoreaMed CrossRef
  5. Pitt, HA, Miyamoto, T, Parapatis, SK, Tompkins, RK, and Longmire, WP (1982). Factors influencing outcome in patients with postoperative biliary strictures. Am J Surg. 144, 14-21.
    Pubmed CrossRef
  6. Davids, PH, Tanka, AK, Rauws, EA, van Gulik, TM, van Leeuwen, DJ, and de Wit, LT (1993). Benign biliary strictures. Surgery or endoscopy?. Ann Surg. 217, 237-43.
    Pubmed KoreaMed CrossRef
  7. Culp, WC, McCowan, TC, Lieberman, RP, Goertzen, TC, LeVeen, RF, and Heffron, TG (1996). Biliary strictures in liver transplant recipients: treatment with metal stents. Radiology. 199, 339-46.
    Pubmed CrossRef
  8. Lopez, RR, Cosenza, CA, Lois, J, Hoffman, AL, Sher, LS, and Noguchi, H (2001). Long-term results of metallic stents for benign biliary strictures. Arch Surg. 136, 664-9.
    Pubmed CrossRef
  9. Molnar, W, and Stockum, AE (1978). Transhepatic dilatation of choledochoenterostomy strictures. Radiology. 129, 59-64.
    Pubmed CrossRef
  10. Mueller, PR, vanSonnenberg, E, Ferrucci, JT, Weyman, PJ, Butch, RJ, and Malt, RA (1986). Biliary stricture dilatation: multicenter review of clinical management in 73 patients. Radiology. 160, 17-22.
    Pubmed CrossRef
  11. Giannini, EG, Testa, R, and Savarino, V (2005). Liver enzyme alteration: a guide for clinicians. CMAJ. 172, 367-79.
    Pubmed KoreaMed CrossRef
  12. Lee, MJ, Mueller, PR, Saini, S, Hahn, PF, and Dawson, SL (1991). Percutaneous dilatation of benign biliary strictures: single-session therapy with general anesthesia. AJR Am J Roentgenol. 157, 1263-6.
    Pubmed CrossRef
  13. Trambert, JJ, Bron, KM, Zajko, AB, Starzl, TE, and Iwatsuki, S (1987). Percutaneous transhepatic balloon dilatation of benign biliary strictures. AJR Am J Roentgenol. 149, 945-8.
    Pubmed KoreaMed CrossRef
  14. Weber, A, Rosca, B, Neu, B, Rösch, T, Frimberger, E, and Born, P (2009). Long-term follow-up of percutaneous transhepatic biliary drainage (PTBD) in patients with benign bilioenterostomy stricture. Endoscopy. 41, 323-8.
    Pubmed CrossRef
  15. Choo, SW, Shin, SW, Do, YS, Liu, WC, Park, KB, and Sung, YM (2006). The balloon dilatation and large profile catheter maintenance method for the management of the bile duct stricture following liver transplantation. Korean J Radiol. 7, 41-9.
    Pubmed KoreaMed CrossRef
  16. Köcher, M, Cerná, M, Havlík, R, Král, V, Gryga, A, and Duda, M (2007). Percutaneous treatment of benign bile duct strictures. Eur J Radiol. 62, 170-4.
    Pubmed CrossRef
  17. Glas, L, Courbière, M, Ficarelli, S, Milot, L, Mennesson, N, and Pilleul, F (2008). Long-term outcome of percutaneous transhepatic therapy for benign bilioenteric anastomotic strictures. J Vasc Interv Radiol. 19, 1336-43.
    Pubmed CrossRef
  18. Janssen, JJ, van Delden, OM, van Lienden, KP, Rauws, EA, Busch, OR, and van Gulik, TM (2014). Percutaneous balloon dilatation and long-term drainage as treatment of anastomotic and nonanastomotic benign biliary strictures. Cardiovasc Intervent Radiol. 37, 1559-67.
    Pubmed CrossRef
  19. Cantwell, CP, Pena, CS, Gervais, DA, Hahn, PF, Dawson, SL, and Mueller, PR (2008). Thirty years’ experience with balloon dilation of benign postoperative biliary strictures: long-term outcomes. Radiology. 249, 1050-7.
    Pubmed CrossRef
  20. Vos, PM, van Beek, EJ, Smits, NJ, Rauws, EA, Gouma, DJ, and Reeders, JW (2000). Percutaneous balloon dilatation for benign hepaticojejunostomy strictures. Abdom Imaging. 25, 134-8.
    Pubmed CrossRef
  21. Gallacher, DJ, Kadir, S, Kaufman, SL, Mitchell, SE, Kinnison, ML, and Chang, R (1985). Nonoperative management of benign postoperative biliary strictures. Radiology. 156, 625-9.
    Pubmed CrossRef
  22. Williams, HJ, Bender, CE, and May, GR (1987). Benign postoperative biliary strictures: dilation with fluoroscopic guidance. Radiology. 163, 629-34.
    Pubmed CrossRef
  23. Salomonowitz, E, Castaneda-Zuniga, WR, Lund, G, Cragg, AH, Hunter, DW, and Coleman, CC (1984). Balloon dilatation of benign biliary strictures. Radiology. 151, 613-6.
    Pubmed CrossRef
  24. Morelli, J, Mulcahy, HE, Willner, IR, Cunningham, JT, and Draganov, P (2003). Long-term outcomes for patients with post-liver transplant anastomotic biliary strictures treated by endoscopic stent placement. Gastrointest Endosc. 58, 374-9.
    Pubmed CrossRef
  25. DePietro, DM, Shlansky-Goldberg, RD, Soulen, MC, Stavropoulos, SW, Mondschein, JI, and Dagli, MS (2015). Long-term outcomes of a benign biliary stricture protocol. J Vasc Interv Radiol. 26, 1032-9.
    Pubmed CrossRef
  26. Saad, WE, Saad, NE, Davies, MG, Lee, DE, Patel, NC, and Sahler, LG (2005). Transhepatic balloon dilation of anastomotic biliary strictures in liver transplant recipients: the significance of a patent hepatic artery. J Vasc Interv Radiol. 16, 1221-8.
    Pubmed CrossRef
  27. Saad, WE (2008). Percutaneous management of postoperative anastomotic biliary strictures. Tech Vasc Interv Radiol. 11, 143-53.
    Pubmed CrossRef
  28. Schumacher, B, Othman, T, Jansen, M, Preiss, C, and Neuhaus, H (2001). Long-term follow-up of percutaneous transhepatic therapy (PTT) in patients with definite benign anastomotic strictures after hepaticojejunnostomy. Endoscopy. 33, 409-15.
    Pubmed CrossRef
  29. Patel, IJ, Davidson, JC, Nikolic, B, Salazar, GM, Schwartzberg, MS, and Walker, TG (2012). Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 23, 727-36.
    Pubmed CrossRef
  30. Venkatesan, AM, Kundu, S, Sacks, D, Wallace, MJ, Wojak, JC, and Rose, SC (2010). Practice guidelines for adult antibiotic prophylaxis during vascular and interventional radiology procedures. Written by the Standards of Practice Committee for the Society of Interventional Radiology and Endorsed by the Cardiovascular Interventional Radiological Society of Europe and Canadian Interventional Radiology Association. J Vasc Interv Radiol. 21, 1611-30.
    CrossRef
  31. Lillemoe, KD (1997). Benign post-operative bile duct strictures. Baillieres Clin Gastroenterol. 11, 749-79.
    CrossRef
  32. Röthlin, MA, Löpfe, M, Schlumpf, R, and Largiadèr, F (1998). Long-term results of hepaticojejunostomy for benign lesions of the bile ducts. Am J Surg. 175, 22-6.
    Pubmed CrossRef
  33. Kakani, NK, Puckett, M, Cooper, M, and Watkinson, A (2006). Percutaneous transhepatic use of a cutting balloon in the treatment of a benign common bile duct stricture. Cardiovasc Intervent Radiol. 29, 462-4.
    Pubmed CrossRef
  34. Sheridan, JS, and Maclennan, AC (2007). Percutaneous transhepatic use of a cutting balloon in the treatment of a benign common bile duct stricture. Cardiovasc Intervent Radiol. 30, 346.
    Pubmed CrossRef
  35. Atar, E, Bachar, GN, Eitan, M, Graif, F, Neyman, H, and Belenky, A (2007). Peripheral cutting balloon in the management of resistant benign ureteral and biliary strictures: long-term results. Diagnostic Interv Radiol. 13, 39-41.
  36. Saad, WE, Davies, MG, Saad, NE, Waldman, DL, Sahler, LG, and Lee, DE (2006). Transhepatic dilation of anastomotic biliary strictures in liver transplant recipients with use of a combined cutting and conventional balloon protocol: technical safety and efficacy. J Vasc Interv Radiol. 17, 837-43.
    Pubmed CrossRef
  37. Hausegger, KA, Kugler, C, Uggowitzer, M, Lammer, J, Karaic, R, and Klein, GE (1996). Benign biliary obstruction: is treatment with the Wallstent advisable?. Radiology. 200, 437-41.
    Pubmed CrossRef
  38. Costamagna, G, Shah, SK, and Tringali, A (2003). Current management of postoperative complications and benign biliary strictures. Gastrointest Endosc Clin N Am. 13, Array-48.
    CrossRef
  39. Gwon, DI, Ko, GY, Sung, KB, Kim, JH, and Yoon, HK (2011). Percutaneous transhepatic treatment of postoperative bile leaks: prospective evaluation of retrievable covered stent. J Vasc Interv Radiol. 22, 75-83.
    CrossRef
  40. Gwon, DI, and Laasch, HU (2015). Radiological approach to benign biliary strictures. Gastrointest Interv. 4, 9-14.
    CrossRef
  41. Tringali, A, Blero, D, Boškoski, I, Familiari, P, Perri, V, and Devière, J (2014). Difficult removal of fully covered Self Expandable Metal Stents (SEMS) for benign biliary strictures: the “SEMS in SEMS” technique. Dig Liver Dis. 46, 568-71.
    Pubmed CrossRef
  42. Petrtýl, J, Brha, R, Horák, L, Zádorová, Z, Dosedel, J, and Laasch, HU (2010). Management of benign intrahepatic bile duct strictures: initial experience with polydioxanone biodegradable stents. Endoscopy. 42, E89-90.
    Pubmed CrossRef
  43. Jones, L, Moir, J, Brown, C, Williams, R, and French, JJ (2014). The novel use of a biodegradable stent placed by percutaneous transhepatic cholangiography for the treatment of a hepaticojejunostomy biliary leak following an extended left hepatectomy and pancreaticoduodenectomy. Ann R Coll Surg Engl. 96, e1-3.
    Pubmed KoreaMed CrossRef
  44. Mauri, G, Michelozzi, C, Melchiorre, F, Poretti, D, Tramarin, M, and Pedicini, V (2013). Biodegradable biliary stent implantation in the treatment of benign bilioplastic-refractory biliary strictures: Preliminary experience. Eur Radiol. 23, 3304-10.
    Pubmed CrossRef
  45. James, SK, Stenestrand, U, Lindbäck, J, Carlsson, J, Scherstén, F, and Nilsson, T (2009). Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med. 360, 1933-45.
    Pubmed CrossRef
  46. Shi, J, Lv, Y, Yu, L, Zhang, B, Zhang, X, and Fan, C (2013). Interest of a new biodegradable stent coated with paclitaxel on anastomotic wound healing after biliary reconstruction. Eur J Gastroenterol Hepatol. 25, 1415-23.
    Pubmed CrossRef
  47. Jang, SI, Kim, JH, You, JW, Rhee, K, Lee, SJ, and Kim, HG (2013). Efficacy of a metallic stent covered with a paclitaxel-incorporated membrane versus a covered metal stent for malignant biliary obstruction: a prospective comparative study. Dig Dis Sci. 58, 865-71.
    CrossRef
  48. Shatzel, J, Kim, J, Sampath, K, Syed, S, Saad, J, and Hussain, ZH (2016). Drug eluting biliary stents to decrease stent failure rates: a review of the literature. World J Gastrointest Endosc. 8, 77-85.
    Pubmed KoreaMed CrossRef